New treatment for horizontal bone loss in the mouth
Official title: MINE-MS for horizontal bone loss treatment
Funded at University of Missouri-Columbia · NIH-10800666 · Data updated 2026-11-12
This study is testing a new injectable treatment designed to help rebuild the bone lost due to gum disease, which can lead to tooth loss, and it aims to make this treatment even better by adding a special ingredient that helps attract healing cells to the area.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | January 17, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $366,367 |
| NIH project number | 5R01DE029808-05 |
| Project ID | NIH-10800666 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are experiencing horizontal alveolar bone loss due to periodontitis.
✕Less likely to help
Patients with vertical bone loss or those who do not have periodontitis may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment for horizontal alveolar bone loss caused by periodontitis, a common oral disease that leads to tooth loss in adults. The approach involves creating an innovative injectable biomaterial called MINE-MS, which mimics the extracellular matrix and promotes bone regeneration. The study aims to enhance the effectiveness of this treatment by incorporating a specific peptide that attracts stem cells essential for healing. Patients may benefit from improved outcomes in managing their oral health and preventing tooth loss.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from periodontitis-related bone loss, potentially preserving their teeth.
How similar studies have gone: While there has been some research on bone regeneration techniques, the specific approach using MINE-MS and the E7 peptide is novel and has not been extensively tested.
Where this research is happening
-
University of Missouri-Columbia
Columbia, United States Active
Researchers
- Principal investigator: Liu, Xiaohua — University of Missouri-Columbia
- Study coordinator: Liu, Xiaohua
Related research
Other NIH-funded projects on the same topics.
-
How HIV and HIV meds affect jaw bone and teeth
This project looks at how HIV, its treatment, and immune changes may cause jawbone and tooth loss in people living with HIV.
-
Periodontitis and HIV treatment–related bone loss in the jaw and teeth
This project studies how HIV and its treatment affect jawbone and tooth loss in people living with HIV, aiming to understand and reduce bone damage around teeth.
-
Molecular clues to bone loss from disuse
This project looks for genes that influence bone loss when people or animals don’t move much, like during bed rest or spaceflight.
-
Oral-Gut–Bone Links in Periodontitis and Bone Loss
This research explores how gum disease could affect bone health by studying the connection between the mouth, gut, and bones in adults.
-
Bone health restoration after spinal cord injury through Wnt signaling and exercise
Aims to find a long-term way to preserve and rebuild bone in people with spinal cord injury, especially veterans, by combining exercise and bone-building signals.
-
Urine cadmium and bone health in older adults
This project looks at whether long-term cadmium exposure, measured in urine, is linked to bone loss and fractures in older adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.